PHARMA TECH

Iktos Announces Deployment of Their AI for Drug Design Software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Iktos | December 09, 2021

Iktos Announces Deployment of Their AI for Drug Design Software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Hengrui Pharma’s drug discovery programmes.

Iktos has released Makya™, a generative AI-driven de novo design software for Multi-Parametric Optimization (MPO), available either as a SaaS platform or for implementation on customer premises or in the customer’s Virtual Private Cloud (VPC). Makya’s user-friendly interface enables it to be used by medicinal or computational chemists. Makya™ can also be operated as a Python package through a Jupyter notebook interface.

Iktos’ AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process, by automatically designing virtual novel molecules that have desired activities for treating a given disease. This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for drug discovery and development.

Innovation is the core development strategy. Hengrui has a strong interest in exploring and utilizing enabling technologies, such as AI, to transform and accelerate the discovery of innovative medicines. We are excited about the opportunity to use Iktos’ proprietary AI platform to beef up our drug design and discovery capability to better address unmet clinical needs”.


Dr. Weikang Tao, Vice President of Hengrui Pharma and CEO of R&D Centers

"We are very pleased to collaborate with Hengrui Pharma, a leading global pharmaceutical company based in China. We are excited and proud to announce our first collaboration deal in China pharma sector and to have Hengrui Pharma scientists use our software in their early discovery programs", said Yann Gaston-Mathé, Co-founder and CEO of Iktos. "It is our ultimate goal to facilitate our technology usage by expert drug discovery scientists, who have deep knowledge and understanding of their discovery programs. This way, the promise of AI to dramatically improve drug discovery will have a better chance to be realized and impact therapeutic development. At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of drug discovery by combining our powerful algorithmic technology, our know-how derived from the experience of the many collaborations we have established to date, and an intuitive and user-friendly user interface which is essential to an optimal user experience.”

About Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

About Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. Hengrui Pharma has 8 innovative products marketed and more than 50 clinical-stage innovative candidates, of which 20 are currently under global clinical development. Hengrui Pharma ranked 21st among the top 1,000 global pharma companies announced by Torreya in 2020. Hengrui has been on the Pharma Exec’s annual listing of the top global pharmaceutical companies for the third consecutive year, rising from the 47th in 2019 to the 38th in 2021.


Spotlight

XANAX is the brand name for the drug Alprazolam, a drug belonging to the class of medications called benzodiazepines or “benzos”.

Spotlight

XANAX is the brand name for the drug Alprazolam, a drug belonging to the class of medications called benzodiazepines or “benzos”.

Related News

PHARMACY MARKET

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020

Ascentage Pharma | January 05, 2021

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FDA, following the past ODDs for the therapy of Waldenström macroglobulinemia (WM), ongoing lymphocytic leukemia (CLL), and numerous myeloma (MM). Until this point, four of Ascentage Pharma's investigational drug up-and-comers have been allowed an aggregate of nine ODDs by the US FDA, a record number for any Chinese biopharmaceutical organization. AML is an exceptionally heterogenous hematologic threat that is more normal in the old populace with a middle age at analysis of 68 years1. The latest information from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute (NCI) assessed 19,940 new instances of AML and 11,180 passings from this infection in the United States in 2020. Notwithstanding the critical advances in therapeutics as of late, the 5-year endurance pace of AML stays at 25%–30%, which actually speaks to a huge neglected clinical requirement for treatments with more solid viability and a superior wellbeing profile. The expression "vagrant medications" alludes to drug items produced for the counteraction, finding, and treatment of uncommon illnesses or conditions. In the United States, a vagrant sign is characterized as a sickness or condition with a pervasiveness of under 200,000 patients in the nation. Since the Orphan Drug Act was passed in 1983, the US government has given motivators and strategy backing to support advancement of vagrant medications. Treatments conceded ODDs by the FDA are equipped for different advancement motivators, including a tax break on consumptions brought about in clinical examinations, a waiver of the New Drug Application (NDA) charge, conceivable exploration award granted by the FDA, and above all, 7 years of US market restrictiveness upon endorsement.

Read More

PHARMA TECH

SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases

SciNeuro Pharmaceuticals | October 26, 2021

SciNeuro Pharmaceuticals a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, and Mabylon AG, a leader in the discovery and characterization of human-derived antibodies against therapeutic targets, today announced the establishment of a multi-program collaboration and license agreement. Under the collaboration, MabSciNeuro and Mabylon will collaborate on multiple targets that encompass serious neurological diseases including TAR DNA binding protein-43 (TDP-43) and Apolipoprotein E (APOE) for neurodegenerative diseases for which there are currently no effective treatments. Both TDP-43 and APOE have human genetic evidence causal to ALS and Alzheimer’s disease. SciNeuro will have rights to develop and commercialize resulting product(s) within Greater China, and an option to expand such rights to become worldwide. “We are excited to be collaborating with Mabylon, a leading biotech company with deep expertise and capabilities for identification and characterization of native human antibodies with therapeutic potential. Their platform enables a deeper exploration of human immunology for therapeutic discovery Native human antibody-based approaches have proven successful for the treatment of infectious diseases including COVID-19. Discovery of auto-antibodies to treat other diseases has been more challenging, due in part to the availability of sufficiently large and high-quality sample collections. By working with companies such as Mabylon, possessing both proprietary antibody screening and cloning technology coupled with large, re-contactable patient sera repositories, we are in a strong position to test the hypothesis and exploit human immune responses for novel and differentiated therapeutic candidates for CNS diseases.” Dr. Min Li, Founder and CEO, SciNeuro Pharmaceuticals “Collaborating with SciNeuro and its R&D team allows full exploitation of Mabylon’s human antibody platform by seamlessly bringing our discovery research products forward to pivotal proof of concept. We are thrilled about this collaboration, which combines innovation in drug discovery with great expertise in drug development in the neurological disease area,” added Dr. Alcide Barberis, CEO, Mabylon. About Mabylon AG Mabylon AG is a leading Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat neurodegenerative diseases and allergies. Access to over 100,000 patients per year allows the discovery of extremely rare target-specific human antibodies, additionally providing information about the target’s human biology and safety profile.. About SciNeuro Pharmaceuticals SciNeuro Pharmaceuticals is a leading neuromedicine company focused on elevating the standard of care for patients suffering from neurological diseases. With R&D capabilities located in the major life sciences hubs of Shanghai, China and Rockville, Maryland, SciNeuro is establishing a robust CNS product pipeline through internal innoylon and SciNeuro will work together to discover and develop human auto-antibodies against targets of mutual interest with a goal to develop differentiated biologic therapeutics to treat neurological diseases.

Read More

BUSINESS INSIGHTS

NanoPass and M2N enter strategic development & foundry agreement

NanoPass; M2N | December 23, 2021

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on years of development and production collaboration. M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects. NanoPass's proprietary technology platform is based on hollow, pyramid-shaped, microneedles. It is produced from silicon crystal using MEMS technology. The technology can be used for intradermal delivery of a wide range of injectables including vaccines and therapeutics, aesthetics, cosmetics and more. "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years. It's an amazing thing considering the average lifespan of a company in recent years. During this long period of time, we have built a strong business relationship on the basis of trust. We are excited to provide high quality microneedles to NanoPass as a Prime Manufacturer and to support NanoPass in developing the new business applications as a Strategic R&D Partner." Kyuho Hwang, CEO of Micro2Nano Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production. M2N provides ongoing high-quality products, has a quick response time, and finds ingenious ways to solve complex problems. For us, trust is a key parameter for any partner, and M2N's organizational culture provides just the thing." About M2N M2N has been providing MEMS foundry service since its foundation in 2000. Profound experience and knowhow with MEMS processes enables M2N to co-work with multiple companies for developing new products and provide mass production services based on MEMS technology. Additionally, M2N has developed its own product line including MEMS probe cards for semiconductor wafer testing and MEMS sensors. About NanoPass NanoPass is a pioneer in the development and commercialization of microneedle-based delivery platforms for aesthetics, vaccines and more. MicronJet®600 is FDA 510k cleared, CE marked and has regulatory approval in Russia, Brazil, South Korea, China and more. It is supported by extensive clinical data and approved for the delivery of any substance or drug under the surface of the skin that is approved for this delivery route.

Read More